Healthcare / Medical DevicesKOSDAQ
$1749.00
-121.00 (-6.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-1.7B · quality 57.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$20.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-30.6%
↓Gross Margin
32.2%
↓Debt/Equity
0.45
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.9%
FCF CAGR
—
FCF margin
-8.4%
FCF / Net income
0.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $19.93B · net income $-10.02B · FCF $-1.67B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $19.93B | $19.93B | $19.13B | $20.39B | $20.46B |
| Net Income | $-10.02B | $-10.02B | $-7.31B | $-4.49B | $-6.81B |
| EBITDA | $-3.95B | $-3.95B | $-1.39B | $-1.01B | $-3.91B |
| EPS | -794.00 | -794.00 | -629.00 | -387.00 | -590.00 |
| Gross Margin | 32.2% | 32.2% | 32.3% | 37.7% | 33.0% |
| Operating Margin | -27.0% | -27.0% | -28.0% | -23.6% | -22.0% |
| Net Margin | -50.3% | -50.3% | -38.2% | -22.0% | -33.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.45 | 0.45 | 0.69 | 0.63 | 0.50 |
| Current Ratio | 1.47 | 1.47 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.67B | $-1.67B | $-1.51B | $-9.01B | $-17.50B |
| Returns | |||||
| ROE | -30.6% | -30.6% | -28.4% | -14.0% | -20.4% |
| Valuation | |||||
| P/B | 0.67 | 0.67 | 1.31 | 1.72 | 2.03 |
| Growth & Yield | |||||
| Revenue Growth | 4.1% | 4.1% | -6.2% | -0.3% | — |
| EPS Growth | -26.2% | -26.2% | -62.5% | 34.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-629.00 → -794.00
Residual
-32.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.